Relationship between Diabetes Duration and Real-World Effectiveness of Second-Line Dual OAD Therapy

被引：0
|
作者：
Brath, Helmut
Paldanius, Paeivi M.
Bader, Giovanni
Mathieu, Chantal
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1220-P
引用
收藏
页码：A315 / A316
页数：2
相关论文
共 50 条
  • [41] Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study
    Liu, Yuxiao
    Guo, Xiaofan
    Xu, Peijun
    Song, Yuning
    Huang, Jing
    Chen, Xingyun
    Zhu, Wenbo
    Hao, Jihui
    Gao, Song
    CANCER BIOLOGY & MEDICINE, 2024, 21 (09) : 799 - 812
  • [42] Real-world outcomes of second-line osimertinib for advanced NSCLC patients with EGFR mutation in China
    Ji, W.
    Li, X.
    Cang, S.
    Xiang, Y.
    Li, X.
    Zhang, J.
    Tan, J.
    Wang, Q.
    Jiang, D.
    Zhang, H.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1067 - S1067
  • [43] Rate of patients receiving second-line treatment for metastatic colorectal cancer in a real-world setting
    Ups, Katherine
    Francesconi, Alessandra
    Ryan, Elizabeth G.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 114 - 114
  • [44] REAL-WORLD EFFICACY OF SECOND-LINE THERAPIES FOR HELICOBACTER PYLORI: A POPULATION-BASED STUDY
    Guo, Chuan-Guo
    Leung, Wai Keung
    GASTROENTEROLOGY, 2024, 166 (05) : S433 - S434
  • [45] Direct Cost of Parkinson's Disease: A Real-World Data Study of Second-Line Therapies
    Gomez-Inhiesto, Elisa
    Teresa Acaiturri-Ayesta, Maria
    Ustarroz-Aguirre, Iker
    Camahuali, Diana
    Urtaran-Laresgoiti, Maider
    Basabe-Aldecoa, Marisol
    Nuno-Solinis, Roberto
    Urizar, Elena
    PARKINSONS DISEASE, 2020, 2020
  • [46] Real-world efficacy of second-line therapies for Helicobacter pylori: a population-based study
    Guo, Chuan-Guo
    Jiang, Fang
    Li, Yueyue
    Chen, Yijun
    Wu, Jialin
    Zhang, Shutian
    Leung, Wai K.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (09) : 2263 - 2272
  • [47] A real-world study of TACE combined with regorafenib as a second-line treatment for advanced hepatocellular carcinoma
    Liu, Shaoxing
    Gao, Song
    Guo, Jianhai
    Kou, Fuxin
    Zhang, Xin
    Liu, Baojiang
    Feng, Aiwei
    Wang, Xiaodong
    Chen, Hui
    Zhu, Xu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study
    Yuxiao Liu
    Xiaofan Guo
    Peijun Xu
    Yuning Song
    Jing Huang
    Xingyun Chen
    Wenbo Zhu
    Jihui Hao
    Song Gao
    Cancer Biology & Medicine, 2024, 21 (09) : 799 - 812
  • [49] Real-world characteristics and outcomes of patients with multiple myeloma receiving second-line treatment in England
    Moore, Sally
    Cornic, Laura
    Crossman-Barnes, Christina-Jane
    Jose, Sophie
    Khalaf, Zeyad
    Yong, Kwee
    Soutar, Megan
    Woods, Philip
    EJHAEM, 2025, 6 (01):
  • [50] Using Anlotinib as Second-line and Subsequent Treatments for Advanced Gynecological Malignancies: a Real-world Study
    Wang, Yuping
    Li, Dengke
    Zhang, Yuke
    Liu, Yuese
    Liu, Peimin
    LATIN AMERICAN JOURNAL OF PHARMACY, 2023, 42 (07): : 1407 - 1414
12345